Article
Oncology
Annika Kurreck, Johanna Weckwerth, Dominik P. Modest, Jana K. Striefler, Marcus Bahra, Sven Bischoff, Uwe Pelzer, Helmut Oettle, Stephan Kruger, Hanno Riess, Marianne Sinn
Summary: Isolated pulmonary metastasis, low tumor grading, low postoperative CA 19-9 levels, completeness of adjuvant gemcitabine-based treatment, number of relapse sites, and type of palliative first-line treatment are significant factors affecting overall survival and disease-free survival in patients with recurrent pancreatic ductal adenocarcinoma. The site of relapse and other prognostic factors may help stratify patients for future clinical trials and could impact subsequent survival. Further research is needed to identify differences in tumor biology and relapse patterns, reflecting the varying survival outcomes in PDAC patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Jana Kaethe Striefler, Hanno Riess, Philipp Lohneis, Sven Bischoff, Annika Kurreck, Dominik Paul Modest, Marcus Bahra, Helmut Oettle, Marianne Sinn, Henrik Blaeker, Carsten Denkert, Sebastian Stintzing, Bruno Valentin Sinn, Uwe Pelzer
Summary: High expression of MUC1 in PDAC patients is associated with decreased DFS and OS, suggesting it is a powerful prognostic marker for post-operative pancreatic ductal adenocarcinoma patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sora Kang, Changhoon Yoo, So Heun Lee, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Jae Ho Jeong, Do Hyun Park, Dong Wan Seo, Jin-hong Park, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Bong Jun Kwak, Sarang Hong, Heung-Moon Chang, Baek-Yeol Ryoo, Kyu-pyo Kim, Song Cheol Kim
Summary: This retrospective study evaluated the efficacy and safety of GemCap versus Gem as adjuvant chemotherapy in an Asian population. The results showed that GemCap had better overall survival and consistent clinical outcomes compared to Gem. Further evaluation of optimal adjuvant chemotherapy is necessary due to the emergence of mFOLFIRINOX as the new standard treatment for resected PDAC patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Seo Yeon Kim, Min Jeong Jo, Moon Sup Yoon, Chae Eun Jin, Yu Been Shin, Jae Min Lee, Hee Ji Shin, Joon Gyo Oh, Jae Min Cho, Hyunjun Kim, Hyunjin Park, Yong-Won Choi, Chun-Woong Park, Jin-Seok Kim, Dae Hwan Shin
Summary: This study developed a drug delivery strategy for pancreatic ductal adenocarcinoma using a thermosensitive gel, which successfully achieved controlled release of drugs based on the researchers' tolerance settings. The gel consisted of gemcitabine (GEM) and the mammalian TOR (mTOR) inhibitor rapamycin (RAPA), demonstrating good cytotoxicity and anti-tumor effects in in vitro and in vivo experiments.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Oncology
Tao Ma, Xueli Bai, Qichun Wei, Yongjie Shui, Mengyi Lao, Wen Chen, Bingfeng Huang, Risheng Que, Shunliang Gao, Yun Zhang, Wei Chen, Ji Wang, Tingbo Liang
Summary: This study suggests that adjuvant stereotactic body radiation therapy (SBRT) does not provide a survival benefit or improve local disease control in resected stage II pancreatic adenocarcinoma (PDAC).
Article
Oncology
Evelien J. M. de Jong, Quisette P. Janssen, Tessa F. A. Simons, Marc G. Besselink, Bert A. Bonsing, Stefan A. W. Bouwense, Sandra M. E. Geurts, Marjolein Y. Homs, Vincent E. de Meijer, Vivianne C. G. Tjan-Heijnen, Hanneke W. M. van Laarhoven, Liselot B. J. Valkenburg-van Iersel, Johanna W. Wilmink, Lydia G. van der Geest, Bas Groot Koerkamp, Judith de Vos-Geelen
Summary: In a nationwide cohort of patients with pancreatic ductal adenocarcinoma, adjuvant GEMCAP was associated with superior survival compared to GEM monotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Haorui Li, Yu Guo, Xugang Sun, Yang Lu, Shaofei Chang, Xiuchao Wang, Song Gao, Chuntao Gao, Tiansuo Zhao
Summary: In this retrospective real-world study, adjuvant S-1 chemotherapy was associated with improved survival compared to GEM, while no differences in overall survival or recurrence-free survival were observed for AG compared to GEM.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
R. Nicolle, O. Gayet, P. Duconseil, C. Vanbrugghe, J. Roques, M. Bigonnet, Y. Blum, N. Elarouci, L. Armenoult, M. Ayadi, A. de Reynies, F. Puleo, J. Augustin, J. F. Emile, M. Svrcek, T. Arsenijevic, P. Hammel, M. Giovannini, P. Grandval, L. Dahan, V Moutardier, M. Gilabert, J. L. Van Laethem, J. B. Bachet, J. Cros, J. Iovanna, N. J. Dusetti
Summary: The study demonstrates that the RNA-based GemPred stratification can predict the benefit of adjuvant gemcitabine in PDAC patients.
ANNALS OF ONCOLOGY
(2021)
Article
Medicine, General & Internal
Jana K. Striefler, Jens M. Stieler, Christopher C. M. Neumann, Dominik Geisel, Pirus Ghadjar, Marianne Sinn, Thomas Malinka, Johann Pratschke, Sebastian Stintzing, Helmut Oettle, Hanno Riess, Uwe Pelzer
Summary: This study aimed to determine the maximum tolerable dose of lapatinib in combination with platinum-containing chemotherapy in refractory pancreatic cancer, and to evaluate its safety and efficacy. The maximum tolerable dose was found to be 1250 mg/day, and the combination of lapatinib with platinum-containing chemotherapy was deemed safe in patients with refractory pancreatic cancer.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Jin Ho Choi, Gun He Nam, Jun-man Hong, In Rae Cho, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Sang Hyub Lee
Summary: The combination of cytokine-induced killer (CIK) cell therapy and gemcitabine can effectively suppress systemic metastatic recurrence in pancreatic cancer, showing promising efficacy and good tolerability in an adjuvant setting.
Article
Multidisciplinary Sciences
Mina Emamzadeh, George Pasparakis
Summary: Pancreatic cancer, a deadly malignancy, is typically treated with gemcitabine but with limited success. This study integrated gemcitabine with gold nanoshells, showing improved therapeutic outcomes after laser irradiation and potential for enhanced anti-tumor effects.
SCIENTIFIC REPORTS
(2021)
Article
Engineering, Biomedical
Gaorui Zhang, Nianlu Li, Yafei Qi, Quanqin Zhao, Jinhua Zhan, Dexin Yu
Summary: This study developed carbonaceous nanoparticles loaded with gemcitabine as nanozymes and theranostic platform for MR-guided ferroptosis-chemo synergetic therapy of pancreatic adenocarcinoma. The nanoparticles effectively promoted ferroptosis therapy and achieved synergetic therapy with gemcitabine. The nanoparticles also had high magnetic susceptibility and were used for simultaneous MRI monitoring of the treatment.
ACTA BIOMATERIALIA
(2022)
Article
Oncology
T. Seufferlein, W. Uhl, M. Kornmann, H. Alguel, H. Friess, A. Koenig, M. Ghadimi, E. Gallmeier, D. K. Bartsch, M. P. Lutz, R. Metzger, K. Wille, B. Gerdes, C. C. Schimanski, F. Graupe, V. Kunzmann, I. Klein, M. Geissler, L. Staib, D. Waldschmidt, C. Bruns, U. Wittel, S. Fichtner-Feigl, S. Daum, A. Hinke, L. Blome, A. Tannapfel, A. Kleger, A. W. Berger, A. M. R. Kestler, J. S. Schuhbaur, L. Perkhofer, M. Tempero, A. C. Reinacher-Schick, T. J. Ettrich
Summary: This study aimed to evaluate the efficacy of perioperative or adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that the preoperative chemotherapy group had a higher disease-free survival rate at 18 months compared to the adjuvant chemotherapy group.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Thierry Conroy, Florence Castan, Anthony Lopez, Anthony Turpin, Meher Ben Abdelghani, Alice C. Wei, Emmanuel Mitry, James J. Biagi, Ludovic Evesque, Pascal Artru, Thierry Lecomte, Eric Assenat, Lucile Bauguion, Marc Ychou, Olivier Bouche, Laure Monard, Aurelien Lambert, Pascal Hammel
Summary: The 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma.
Article
Oncology
Michael Guenther, Stefan Boeck, Volker Heinemann, Jens Werner, Jutta Engel, Steffen Ormanns
Summary: Adjuvant chemotherapy can significantly improve the prognosis of patients with UICC stage I pancreatic ductal adenocarcinoma, independent of tumor localization, differentiation, and R status.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Oncology
Felix Krenzien, Nora Nevermann, Alina Krombholz, Christian Benzing, Philipp Haber, Uli Fehrenbach, Georg Lurje, Uwe Pelzer, Johann Pratschke, Moritz Schmelzle, Wenzel Schoening
Summary: This review discusses multimodality treatment strategies for intrahepatic cholangiocarcinoma (iCC). Surgical resection remains the only potentially curative therapeutic option, and adjuvant systemic treatment is recommended. Targeted therapies and interventional treatments such as high-dose brachytherapy and transarterial chemoembolization are being evaluated for unresectable iCC. Any treatment strategy should be discussed in a multidisciplinary tumor board and guided by specialized treatment centers.
Review
Oncology
Sandra Pavicevic, Sophie Reichelt, Deniz Uluk, Isabella Lurje, Cornelius Engelmann, Dominik P. Modest, Uwe Pelzer, Felix Krenzien, Nathanael Raschzok, Christian Benzing, Igor M. Sauer, Sebastian Stintzing, Frank Tacke, Wenzel Schoening, Moritz Schmelzle, Johann Pratschke, Georg Lurje
Summary: Cholangiocarcinoma is a rapidly increasing global malignancy of the biliary tract, often presenting with advanced or unresectable disease. Biomarkers obtained from patients' serum or tumor tissue could help guide therapy and identify those at higher risk of recurrence. Genetic aberrations in cholangiocarcinoma have also been linked with improved response to targeted therapies. This review provides an overview of prognostic and predictive biomarkers in cholangiocarcinoma.
Article
Medicine, General & Internal
Nick Lasse Beetz, Dominik Geisel, Christoph Maier, Timo Alexander Auer, Seyd Shnayien, Thomas Malinka, Christopher Claudius Maximilian Neumann, Uwe Pelzer, Uli Fehrenbach
Summary: This study aimed to use artificial intelligence to analyze baseline CT body composition in pancreatic cancer patients and identify potential imaging predictors of survival. The presence of surgery, sarcopenia, and increased visceral adipose tissue were found to be important factors associated with survival.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Matthaus Felsenstein, Flora Lindhammer, Mathilde Feist, Karl Herbert Hillebrandt, Lea Timmermann, Christian Benzing, Brigitta Globke, Dario Zocholl, Mengwen Hu, Uli Fehrenbach, Bruno Valentin Sinn, Uwe Pelzer, Igor Maximillian Sauer, Johann Pratschke, Thomas Malinka
Summary: This study confirms the improvement in long-term survival of PDAC-resected cancer patients with Pn0, and highlights the significant impact of perineural invasion on the long-term survival of formally curative patients. These findings provide new insights into risk stratification and multimodal treatment strategies for pancreatic cancer patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Safak Guel-Klein, Paulina Schmitz, Wenzel Schoning, Robert Oelinger, Georg Lurje, Sven Jonas, Deniz Uluk, Uwe Pelzer, Frank Tacke, Moritz Schmelzle, Johann Pratschke, Ramin Raul Ossami Saidy, Dennis Eurich
Summary: This study investigated the recurrence and survival of cholangiocellular carcinoma after liver transplantation in relation to tumor type and type of immunosuppression. It was found that patients with recurrent cholangiocellular carcinoma who were not eligible for surgical resection had significantly impaired survival. N1 status at transplantation and histological grading >1 were associated with worse outcomes. Reduced immunosuppression after tumor recurrence improved survival.
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Rolf D. Issels, Stefan Boeck, Uwe Pelzer, Ulrich Mansmann, Pirus Ghadjar, Lars H. Lindner, Markus Albertsmeier, Martin K. Angele, Michael Schmidt, Yujun Xu, Marcus Bahra, Johann Pratschke, Michael Schoenberg, Wolfgang E. Thasler, Christoph Salat, Oliver J. Stoetzer, Wolfram T. Knoefel, Dirk Graf, Rudiger Wessalowski, Verena Keitel-Anselmino, Alfred Koenigsrainer, Michael Bitzer, Daniel Zips, Michael Bamberg, Rainer Fietkau, Oliver Ott, Maciej Kawecki, Lucian Wyrwicz, Piotr Rutkowski, Markus Rentsch, Juliana Ababei, Peter Reichardt, Marco Rigamonti, Bernhard Weber, Sultan Abdel-Rahman, Katharina Tschoep-Lechner, Karl-Walter Jauch, Christiane J. Bruns, Helmut Oettle, Michael von Bergwelt-Baildon, Volker Heinemann, Jens Werner
Summary: In this randomized controlled trial, the addition of cisplatin to gemcitabine with regional hyperthermia did not significantly improve disease-free survival in resected pancreatic ductal adenocarcinoma, but it showed a difference in post-recurrence survival and a trend for improved overall survival.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klumpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel
Summary: This study examined the efficacy of adding the immune checkpoint inhibitor pembrolizumab to the standard chemotherapy regimen for advanced biliary tract cancer. The results showed that the combination treatment significantly improved overall survival compared to chemotherapy alone.
Article
Surgery
Matthaus Felsenstein, Ann-Christin Amini, Sophie Dorfer, Mengwen Hu, Ruonan Wang, Lea Timmermann, Karl Herbert Hillebrandt, Christian Benzing, Uli Fehrenbach, Uwe Pelzer, Igor Maximillian Sauer, Johann Pratschke, Christian Juergensen, Thomas Malinka
Summary: This study presents a novel approach for the internal drainage of anastomotic leakage and peri-anastomotic fluid collections after pancreatic head resection. By retrospectively evaluating 531 patients, the study found that endoscopy-guided treatment demonstrated superior success rates and shorter hospital stays compared to other treatment modalities.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Article
Medicine, General & Internal
Christopher C. M. Neumann, Francois Schneider, Georg Hilfenhaus, Loredana Vecchione, Christian Benzing, Jana Ihlow, Uli Fehrenbach, Thomas Malinka, Ulrich Keilholz, Sebastian Stintzing, Uwe Pelzer
Summary: In addition to being risk factors for pancreatic cancer, parameters such as smoking, diabetes, or obesity might also act as potential prognostic factors for the survival of patients initially diagnosed with pancreatic cancer. By implementing one of the largest retrospective study cohorts, potential prognostic factors for survival were evaluated and various metabolic markers were identified.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Christopher C. M. Neumann, Francois Schneider, Georg Hilfenhaus, Loredana Vecchione, Matthaeus Felsenstein, Jana Ihlow, Dominik Geisel, Steffen Sander, Johann Pratschke, Sebastian Stintzing, Ulrich Keilholz, Uwe Pelzer
Summary: Inflammation markers, including NRL, PLR, LMR, CAR, and the new combined score IBI, have been identified as independent prognostic markers for overall survival in pancreatic cancer patients. These findings highlight the importance of inflammation in pancreatic cancer, provide easily accessible prognostic values, and may aid in patient stratification for trials targeting inflammation or immune response.
Review
Oncology
Timo Alexander Auer, Federico Collettini, Laura Segger, Uwe Pelzer, Raphael Mohr, Felix Krenzien, Bernhard Gebauer, Dominik Geisel, Clarissa Hosse, Wenzel Schoening, Uli Fehrenbach
Summary: cHCC-CCA is a rare form of liver cancer that combines features of both hepatocellular and biliary tract cancer. There is currently no established interventional therapy for cHCC-CCA due to its rarity. This review aims to provide an overview of current radiologic interventions for CCA, review the existing literature, and explore the potential role of these interventions in the treatment of cHCC-CCA in the future.
Article
Radiology, Nuclear Medicine & Medical Imaging
Johannes Kolck, Timo Alexander Auer, Thula Walter-Rittel, Clarissa Hosse, Aboelyazid Elkilany, Adrian Alexander Marth, Uwe Pelzer, Raphael Mohr, Felix Krenzien, Georg Lurje, Wenzel Schoening, Bernd Hamm, Dominik Geisel, Uli Fehrenbach
Summary: This study aimed to develop a predictive model for lymph node metastasis (LNM) in patients with intrahepatic cholangiocarcinoma (iCC) using computed tomography (CT) features. The study found that an LN short axis diameter of ≥ 9 mm had the highest predictive power for LNM. Additionally, the presence of intrahepatic metastasis, hilar tumor infiltration, and tumor growth along the liver capsule were identified as significant imaging features in the predictive model.
ABDOMINAL RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Timo A. Auer, Sebastian Halskov, Uli Fehrenbach, Nora F. Nevermann, Uwe Pelzer, Raphael Mohr, Bernd Hamm, Wenzel Schoening, David Horst, Jana Ihlow, Dominik Geisel
Summary: This study aimed to investigate the value of gadoxetic acid-enhanced MRI for noninvasive subtype differentiation of HCCs in a western population. The results showed that Gd-EOB-MRI can be a valuable tool for noninvasive HCC subtype differentiation.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
N. Nevermann, J. Bode, M. Vischer, F. Krenzien, G. Lurje, U. Pelzer, U. Fehrenbach, T. A. Auer, M. Schmelzle, J. Pratschke, W. Schoening
Summary: This study investigated the clinical management and outcome of borderline resectable intrahepatic cholangiocarcinomas (ICC) and the effect of hypertrophy induction of the future liver remnant prior to resection. The results showed comparable perioperative morbidity rates between the hypertrophy induction group and the control group. Overall survival rates were similar, but were notably reduced in cases with additional risk factors such as multifocal tumor, lymph node metastasis, and disease progression during hypertrophy.